Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÇÁ·Î¶ôƾ¼±Á¾¿¡ ´ëÇÑ ¼ö¼úÀû Ä¡·á È¿°ú Prolactinoma : Surgical Treatment and Outcome

´ëÇѽŰæ¿Ü°úÇÐȸÁö 1998³â 27±Ç 3È£ p.357 ~ 362
¼Ò¼Ó »ó¼¼Á¤º¸
±ÇÅÃÇö/Taek Hyun Kwon Á¤¿ë±¸/Á¶ÅÂÇü/¹ÚÁ¤À²/¹ÚÀ±°ü/Á¤Èï¼·/À̱âÂù/ÀÌÈÆ°©/Yong Gu Chung/Tai Hyoung Cho/Jung Yul Park/Youn Kwan Park/Heung Seob Chung/Ki Chan Lee/Hoon Kap Lee

Abstract

°á·Ð
ÀúÀÚµéÀº ÃÖ±Ù 7³â°£ º» ±³½Ç¿¡¼­ ¼ö¼ú ½ÃÇàÇÏ¿´´ø 104¸íÀÇ ³úÇϼöü ¼±Á¾ ȯÀÚ ¹× ¸é¿ª
Á¶Á÷È­Çп°»ö»ó ÇÁ·Î¶ôƾ ¼±Á¾À¸·Î Áø´ÜµÇ¾ú´ø 37¸íÀÇ È¯ÀÚµéÀ» ´ë»óÀ¸·Î ÀÓ»ó ºÐ¼®À» ½ÃÇà
ÇÑ °á°ú ´ÙÀ½°ú °°Àº °á·ÐÀ» ¾ò¾ú´Ù
1) Àüü 104¸íÀÇ ³úÇϼöü ¼±Á¾ ȯÀÚ Áß ÇÁ·Î¶ôƾ¼±Á¾ÀÌ 37¸í(35.6%)À¸·Î °¡Àå ¸¹¾ÒÀ¸¸ç,
ºñºÐºñ¼º ¼±Á¾ ¼ºÀåÈ£¸£¸ó ºÐºñ¼±Á¾ÀÇ ¼øÀ̾ú´Ù.
2) ³úÇϼöü ¼±Á¾Àº ³²³àºñ 1 : 1.7·Î ¿©¼º¿¡¼­ È£¹ßÇÏ¿´À¸¸ç, ÇÁ·Î¶ôƾ¼±Á¾ÀÇ °æ¿ì ³²³àºñ
1 : 3.1·Î ÀÌ·¯ÇÑ ¿©¼ºÈ£¸£¸óÀÌ ´õ¿í ¶Ñ·ÇÇÏ¿´´Ù.
3) ¼ö¼ú ´ç½Ã ¿¬·ÉÀº Àüü ȯÀÚÀÇ °æ¿ì Æò±Õ 40.6¼¼ÀÎ ¹Ý¸é, ÇÁ·Î¶ôƾ¼±Á¾ÀÇ °æ¿ì Æò±Õ 32.2
¼¼·Î º¸´Ù ÀþÀº ³ªÀÌ¿¡¼­ ¹ß»ýÇÏ¿´À¸¸ç ÀÌ´Â ÇÁ·Î¶ôƾ¼±Á¾ÀÇ °æ¿ì Ư¡ÀûÀΠȣ¸£¸ó °ú´ÙÁõ
»óÀ¸·Î Á¶±âÁø´ÜÀÌ °¡´ÉÇϱ⠶§¹®ÀÏ °ÍÀ¸·Î »ç·áµÈ´Ù.
4) ¼ö¼úÀü Ç÷Áß ÇÁ·Î¶ôƾġ´Â Æò±Õ 1027.9ng/mlÀ̾úÀ¸³ª ¼ö¼ú ÈÄ 7¡­10ÀÏ »çÀÌ¿¡ ÃøÁ¤ÇÑ Ç÷
Áß ÇÁ·Î¶ôƾġ´Â Æò±Õ 767.8ng/mlÀ¸·Î ¾à 25.3%ÀÇ °¨¼ÒÀ²À» º¸¿´´Ù.
5) Á¾¾çÀÇ Å©±â´Â ¹Ì¼¼¼±Á¾ 13¸í, °Å´ë¼±Á¾ 24¸íÀ̾úÀ¸¸ç ¼ö¼úÀü Ç÷Áß ÇÁ·Î¶ôƾġ°¡
200ng/m1ÀÌÇÏÀÎ °æ¿ì °Å´ë¼±Á¾ÀÌ 42.1%ÀÎ ¹Ý¸é, Ç÷Áß ÇÁ·Î¶ôƾġ°¡ 200ng/mlÀÌ»óÀÎ °æ¿ì´Â
°Å´ë¼±Á¾ÀÌ 88.9%¸¦ Â÷ÁöÇÏ¿© Á¾¾çÀÇ Å©±â¿Í Ç÷Áß ÇÁ·Î¶ôƾġ»çÀÌ¿¡ »ó°ü°ü°è°¡ ÀÖÀ½À» ¾Ë
¼ö ÀÖ¾ú´Ù
6) ¼ö¼úÀü Ç÷Áß ÇÁ·Î¶ôƾġ°¡ 200ng/m1ÀÌÇÏÀ̾ú´ø °æ¿ì ¹«¿ù°æÀº 76.5%¿¡¼­ È£ÀüµÇ¾ú°í ¼ö
¼úÈÄ Ç÷Áß ÇÁ·Î¶ôƾġ´Â 73.7%¿¡¼­ Á¤»óÈ­µÇ¾ú´Ù. ±×·¯³ª ¼ö¼úÀü Ç÷Áß ÇÁ·Î¶ôƾġ°¡
200ng/m1ÀÌ»óÀ̾ú´ø °æ¿ì¿¡´Â ¹«¿ù°æÀº 30%¿¡¼­¸¸ È£ÀüµÇ¾ú°í ¼ö¼úÈÄ Ç÷Áß ÇÁ·Î¶ôƾġ´Â
22.2%¿¡¼­ ¸¸ Á¤»óÈ­µÇ¾ú´Ù.
7) ¼ö¼úÈÄ °á°ú¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ´Â ¿©·¯ ¿äÀεé Áß ¼ö¼úÀü Ç÷Áß ÇÁ·Î¶ôƾġ°¡ Áß¿äÇÑ °Í
À¸·Î »ç·áµÈ´Ù.
#ÃÊ·Ï#
Thirty-seven patients with prolactinoma treated over a seven-year period were
retrospectively reviewed. During the same period, a total of 104 patients with pituitary
adenoma were treated at our hospital, and among them, prolactinoma was the most
frequently occurring tumor(35.6%) ; it was followed by nonfunctional adenoma and
growth hormone-secreting adenoma. A female preponderance was observed with a male
to female ratio of 1 : 3.1. Prolactinoma patients were diagnosed at a younger age than
pituitary adenoma patients in general ; it seemed that the typical symptoms of prolactin
excess facilitated early diameter as seen on CT or MRI image. Clinical symptoms or
were related to mass effect(visual field defect, loss of visual acuity, headache) and/or
hormone excess(amenorrhea, galactorrhea). Mean preoperative serum prolactin level was
a preoperative serum prolactin level below 200ng/ml, amenorrhea improved in 76.5% of
cases and serum prolactin level normalized in 73.7%, but in cases where this level was
over 200ng/ml, amenorrhea improved in only 30% of cases and serum prolactin level
returned to normal in only 22.2%. It appears that surgical outcome was mostly
influenced by the preoperative serum prolactin level.

Å°¿öµå

Prolactinoma; Serum prolactin level;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS